Key facts
- It has raised $7.0M; the latest was Merger/Acquisition in May 2025.
- Notable investors include Gaingels, TEDCO, Early Light Ventures, Johns Hopkins Technology Ventures, Riptide Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Previse (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Previse (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Previse (Biotechnology)
Developer of a novel diagnostic early-detection system designed to detect esophageal cancer and its precancer in the early stages. The company's system offers detection and prevention of esophageal cancer to resolve diagnostic and prognostic uncertainty, enabling clinicians to prevent, detect and treat gastrointestinal diseases.
- Sector
- Healthcare
- HQ
- Halethorpe, MD, United States
- Founded
- 2018
- Employees
- 10
- Website
- previsedx.com/
- Ownership
- Privately Held (backing)
Previse (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Previse (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Previse (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.